lfb-r603
mAbexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2008 (NCT01098188)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD20BINDING AGENT
B-lymphocyte antigen CD20 binding agent
- B-lymphocyte antigen CD20CROSS-LINKING AGENT
MS4A1 cross-linking agent
- B-lymphocyte antigen CD20INHIBITOR
MS4A1 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109348 ↗
Also known as
- lfb-r603
- lfb-r603
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01098188 | Phase 1 | Nov 1, 2008 | Laboratoire français de Fractionnement et de Biotechnologies |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Laboratoire français de Fractionnement et de Biotechnologies | For profit | 1 | 1 | 1 | 2008 |
1 organizations
Page 1 / 1